TABLE 1.
Clinical Data of 19 Patients with PDAC Examined by 68Ga-FAPI PET/CT
| Patient | Age (y) | Sex | Previous surgery | Previous chemotherapy | Previous radiation | Clinical indication | FAPI variant | Acquisition time (min after injection) |
| 1 | 52 | M | Whipple | FOLFIRINOX | Mediastinal lymph nodes | Recurrence/PD | FAPI-4 | 60 |
| 2 | 52 | M | Whipple | No | No | Recurrence/PD | FAPI-4 | 60 |
| 3 | 52 | F | No | FOLFIRINOX | No | Recurrence/PD | FAPI-46 | 10/60/180 |
| 4 | 58 | M | Total pancreatectomy | FOLFIRINOX | No | Recurrence/PD | FAPI-4 | 60 |
| 5 | 58 | M | no | No | No | Primary staging | FAPI-4 | 60 |
| 6 | 59 | F | Distal pancreatectomy | Gem | No | Recurrence/PD | FAPI-46 | 10/60/180 |
| 7 | 60 | M | No | FOLFIRINOX | No | Recurrence/PD | FAPI-4 | 60 |
| 8 | 60 | M | No | No | No | Primary staging | FAPI-4 | 60 |
| 9 | 61 | F | Whipple | Gem + Cap | No | Primary staging | FAPI-4 | 60 |
| 10 | 64 | F | Whipple | FOLFIRINOX | No | Recurrence/PD | FAPI-4 | 60 |
| 11 | 64 | M | Distal pancreatectomy | FOLFIRINOX | No | Recurrence/PD | FAPI-4 | 60 |
| 12 | 65 | F | Whipple | FOLFIRINOX | No | Primary staging | FAPI-4 | 60 |
| 13 | 66 | F | no | Gem | no | Primary Staging | FAPI-4 | 60 |
| 14 | 67 | F | Distal pancreatectomy | FOLFIRINOX | No | Recurrence/PD | FAPI-4 | 60 |
| 15 | 68 | F | No | No | No | Primary staging | FAPI-4 | 60 |
| 16 | 74 | M | pp-Whipple | Cap + Ox | No | Recurrence/PD | FAPI-4 | 60 |
| 17 | 76 | F | pp-Whipple | Gem + nab-paclitaxel | No | Recurrence/PD | FAPI-4 | 60/180 |
| 18 | 79 | M | No | No | No | Primary staging | FAPI-4 | 60 |
| 19 | 80 | M | No | Gem + nab-paclitaxel | Primary tumor | Recurrence/PD | FAPI-46 | 10/60/180 |
FOLFIRINOX = 5-fluorouracil, leukovorin, irinotecan, and oxaliplatin; Gem = gemcitabine; Cap = capecitabine; Ox = oxaliplatin; pp-Whipple: pylorus-preserving Whipple procedure.